Markets:

Overview

News

Currencies

International

Treasuries

Becton Dickinson (NY:BDX)

155.93 +2.96 (+1.94%)

Streaming Delayed Price Updated: 2:05 PM EDT, Jul 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Becton Dickinson

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Becton, Dickinson's Debt Overview ↗

March 10, 2023

Via Benzinga

(BDX) - Analyzing Becton, Dickinson's Short Interest ↗

March 09, 2023

Via Benzinga

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

March 01, 2023

By David Willey, Benzinga

Via TheNewswire.com

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

March 01, 2023

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

Via News Direct

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company? ↗

March 01, 2023

The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices.

Via Benzinga

Looking Into Becton's Return On Capital Employed ↗

February 03, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Becton, Dickinson ↗

February 03, 2023

Via Benzinga

A Bullish Sign Appears On Becton, Dickinson's Chart ↗

January 24, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Becton, Dickinson ↗

January 06, 2023

Via Benzinga

Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11

March 01, 2023

Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its

Via MarketBeat

Topics Initial Public Offering

The 7 Best Dividend Growth Stocks for Long-Term Investors ↗

February 22, 2023

Although passive income is always useful under uncertain times, why not get capital gains through the best dividend growth stocks?

Via InvestorPlace

Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software ↗

February 17, 2023

Becton Dickinson and Co (NYSE: BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software.

Via Benzinga

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO ↗

February 15, 2023

Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in...

Via Benzinga

2 Medical Stocks to Watch Heading Into 2023 ↗

December 31, 2022

The two healthcare companies easily outdid the S&P 500 this year.

Via The Motley Fool

Embecta Stock Tumbles On Mixed Q4 Results, Softer Guidance ↗

December 20, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Becton, Dickinson ↗

December 12, 2022

Via Benzinga

Why Embecta Stock Popped by Nearly 13% Today ↗

February 14, 2023

Twin beats and raised guidance make for a good day on the market for the diabetes care specialist.

Via The Motley Fool

Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products

January 17, 2023

By David Willey, Benzinga

Via TheNewswire.com

Topics Economy

Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products

January 17, 2023

Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products

Via News Direct

Topics Economy

Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products ↗

January 17, 2023

Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the...

Via Benzinga

Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029

January 12, 2023

EQNX::TICKER_START (NASDAQ:STSS),(NYSE:BDX),(NYSE:CAH),(NYSE:NVO),(OTCPK:TRUMY),(NASDAQ:STSSW) EQNX::TICKER_END

Via FinancialNewsMedia

Becton Dickinson, Freeport-McMoRan, GXO Logistics And This Mid-Cap ETF On CNBC's 'Final Trades' ↗

January 10, 2023

On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named iShares Core S&P Mid-Cap ETF (NYSE: IJH), saying that "mid-c

Via Benzinga

Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry ↗

January 09, 2023

Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development...

Via Benzinga

2 Relatively Safe Dividend Stocks to Buy Today and Hold Forever ↗

January 02, 2023

They already have extensive track records of success, and there's even more on the way.

Via The Motley Fool

2 Top Dividend Kings to Buy for the Long Haul ↗

December 14, 2022

No matter how much changes, these two healthcare giants keep performing.

Via The Motley Fool

Reliable Passive Income: an Analysis on Dividend Kings ↗

December 13, 2022

A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 01, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗

December 12, 2022

Via Benzinga

NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company ↗

November 11, 2022

Piper Sandler cut the price target on Becton, Dickinson and Company (NYSE: BDX) from $255 to $245. Piper Sandler analyst Jason Bednar maintained the stock with a Neutral. Becton, Dickinson shares...

Via Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today ↗

November 10, 2022

Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.41% on an annualized basis producing an average annual return of 11.05%. Currently, Becton, Dickinson has a market...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.